Trovagene this week announced the commercial availability of its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus test.

The test is designed to accurately identify the presence or absence of 15 known high-risk HPV strains, and has a published sensitivity of 93 percent and specificity of 96 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.